84765-24-2

Usage

Uses

Used in Organic Synthesis:
(R)-2-((tert-Butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate is used as an intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows for selective reactions and functional group manipulations, making it a valuable component in the synthesis of complex molecules.
Used as a Protecting Group for Amines:
In the field of organic chemistry, (R)-2-((tert-Butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate serves as a protecting group for amines. The Boc group can be selectively removed under mild acidic conditions, allowing for the controlled deprotection of the amine group when needed. This selective protection is crucial in multi-step organic synthesis, where unwanted side reactions must be minimized.
Used in Peptide Synthesis:
(R)-2-((tert-Butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate is used as a reagent in the synthesis of peptides. The Boc-protected amino group allows for the stepwise assembly of peptide chains, with the Boc group being removed at the appropriate stage to reveal the free amine for further elongation of the peptide.
Used in Pharmaceutical Synthesis:
(R)-2-((tert-Butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate is also used in the synthesis of pharmaceuticals, where its unique structure can be exploited to create novel drug candidates. The Boc protection strategy can be particularly useful in the development of complex drug molecules, where precise control over the synthesis process is required.
Used in Material Science:
(R)-2-((tert-Butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate may be used in the development of new materials, such as polymers or other advanced materials, where its unique chemical properties can be utilized to create materials with specific characteristics or functions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-2-((tert-Butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate can be used as a starting material or a building block for the design and synthesis of new drug candidates. Its versatility in organic synthesis and its potential to be incorporated into complex molecular structures make it a valuable tool in the search for new therapeutic agents.

Upstream product

• 28875-17-4 (S)-N-(tert-butoxycarbonyl)alanine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 545433-88-3 N-(tert-butyloxycarbonyl)-L-isoleucinol 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 16112-59-7 4-methyl-2-oxazolidone 
• 172695-22-6 (2-cyano-1(S)-methylethyl)carbamic acid, 1,1-dimethylethyl ester 
• 1185453-83-1 C₁₄H₂₀BrNO₂S 
• 1185454-25-4 C₁₄H₁₈BrF₂NO₃ 
• 1643565-08-5 (S)-tert-butyl 6-methyl-3-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine-5(4H)carboxylate 
• 1431532-85-2 tert-butyl ((2S)-1-((2-(4-propoxyphenyl)-1-benzofuran-6-yl)oxy)propan-2-yl)carbamate 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationship studies of L-amino alcohol derivatives as broad-spectrum antifungal agents

To discover broad spectrum antifungal agents, two strategies were applied, and a novel class of L-amino alcohol derivatives were designed and synthesized. 3-F substituted compounds 14i, 14n, 14s and 14v exhibited excellent antifungal activities with broad antifungal spectra against C. albicans and C. tropicalis, with MIC values in the range of 0.03–0.06 μg/mL, and against A. fumigatus and C. neoformans, with MIC values in the range of 1–2 μg/mL. Notably, Compounds 14i, 14n, 14s and 14v also displayed moderate activities against fluconazole-resistance strains 17# and CaR that were isolated from AIDS patients. Moreover, only compounds in the S-configuration showed antifungal activity. Preliminary mechanistic studies showed that the potent antifungal activity of compound 14v stemmed from inhibition of C. albicans CYP51. Compounds 14n and 14v were almost nontoxic to mammalian A549 cells, and their stability in human plasma was excellent.

Synthesis and evaluation of chiral β-amino acid-based low-molecular-weight organogelators possessing a methyl/trifluoromethyl side chain

The synthesis and gelation properties of chiral β-amino acid-based low-molecular-weight organogelators, possessing methyl/trifluoromethyl side chains, are reported. The structure of the side chain and chirality were found to be important parameters affecting the gelation ability. The pure enantiomer of the trifluoromethylated β-amino acid displayed good gelation properties due to the formation of fibrillar networks, driven by enhanced amide hydrogen bonding. An investigation of the effects of the alkyl chain length showed that longer alkyl chain improved the gelation ability, yet the same supramolecular structure was observed in all, as well as an odd-even effect in both the melting points and Tg values.

Total Synthesis and Stereochemical Revision of the Anti-Tuberculosis Peptaibol Trichoderin A

The first total synthesis of the postulated structure of the aminolipopeptide trichoderin A and its epimer are reported. A late-stage solution phase C-terminal coupling was employed to introduce the C-terminal aminoalcohol moiety. This methodology provides a foundation to prepare analogues of trichoderin A to establish a structure-activity relationship. NMR spectroscopic analysis established that the C-6 position of the 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue in trichoderin A possesses an (R)-configuration as opposed to the originally proposed (S)-configuration.

A rapid entry to amino acid derived diverse 3,4-dihydropyrazines and dihydro[1,2,3]triazolo[1,5-a]pyrazines through 1,3-dipolar cycloaddition

An efficient, general and practical synthesis of diverse 3,4-dihydropyrazines, 6,7-dihydro-[1,2,3]triazolopyrazines and 7,8-dihydro-[1,2,3]triazolodiazepines through intramolecular 1,3-dipolar cycloaddition from amino acid derived common intermediates with high yields is described. Moreover, one-pot access to optically active 3-aryl substituted 6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazines in the palladium-copper co-catalytic system has also been achieved in this work. The easy substrate availability and operational simplicity make the process suitable for further exploration. This journal is the Partner Organisations 2014.

BICYCLIC COMPOUND

The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

Syntheis of new chiral 5,6,7,8-tetrahydrotetrazolo[1,5-a]pyrazines from α-amino acid derivatives following "click" chemistry

An efficient and practical synthesis of new chiral fused tetrazoles have been synthesized following [3+2] cycloaddition reaction starting from α-amino acid derivatives.

Synthesis of new chiral 4,5,6,7-tetrahydro[1,2,3]triazolo[1,5-a]pyrazines from α-amino acid derivatives under mild conditions

A practical and efficient regioselective synthesis of several new chiral 4,5,6,7-tetrahydro[1,2,3]triazolo[1,5-a]pyrazines is described from α-amino acid derivatives following intramolecular 'click' reaction as the key step. The method obviates product pu

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Chemoenzymatic synthesis of 4-amino-2-hydroxy acids: A comparison of mutant and wild-type oxidoreductases

We describe a new chemoenzymatic synthesis of enantiopure 4-amino-2-hydroxy acids using two biotransformations in a single-pot process in aqueous medium. These compounds are valuable as γ-turn mimics for investigations into the secondary structure of peptides. The enzyme substrates are a series of carbobenzyloxy (CBZ)-protected 4-amino-2-keto esters, prepared efficiently from the L-amino acids, alanine, leucine, phenylalanine, and valine. First, the α-amino acids were converted to the corresponding β-amino acids in a simple five-step procedure. A further one-carbon homologation via ozonolysis of the corresponding β-keto cyanophosphoranes gave the required α-keto esters in good yield. The enzyme catalyzed hydrolyses of all the α-keto esters to the corresponding α-keto acids proceeded smoothly with the lipase from Candida rugosa. Using the same reaction pot, it was found that wild-type lactate dehydrogenases from either Bacillus stearothermophilus CBS-LDH) or Staphylococcus epidermidis (SE-LDH) could be used to specifically reduce the ketone of the alanine-derived α-keto acid 2, giving the (S)- and CR)-2-hydroxy acids, respectively, in good yields. However, the more bulky α-keto acids 3, 4, and 5 (derived from valine, leucine, and phenylalanine) were not substrates for these enzymes. In contrast, the genetically engineered H205Q mutant of D-hydroxyisocaproate dehydrogenase proved to be an ideal catalyst for the reduction of all the α-keto acids 2-5, giving excellent yields of the CBZ-protected (2R,4S)-4-amino2-hydroxy acids as single diastereomers. This genetically engineered oxidoreductase has great potential value in synthesis due to its broad substrate specificity and high catalytic activity. For example, reduction of 1 mmol of N-protected (S)-4-amino-2-oxopentanoic acid 2 took just 4 h with the H205Q mutant giving, after esterification, the CR)-2-alcohol 25 in 85% yield, whereas with SE-LDH the reaction required 4 days to give a 67% yield of 25.

Sparsomicin (Sc-Rs) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (Sc-Rs) compounds

The invention relates to novel sparsomycin (Sc-Rs) compounds having valuable antitumor activity, and to a process for their preparation and pharmaceutical compositions containing such novel compounds. The novel compounds satisfy the general formula